NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
10 trialsNCT06465017 2026-04-20
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Phase NA Terminated
NCT01580618 2026-04-14
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
Kaiser Permanente
Phase 2/3 Terminated
NCT03621124 2026-04-13
Maladaptive Adipose Tissue Activity in Cancer
Virginia Commonwealth University
Terminated
NCT07479381 2026-04-09
CLEAR
Harbinger Health
Terminated
NCT04824859 2026-04-03
eGAP
University of Rochester
Phase NA Terminated
NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT05933070 2026-03-30
LAUREL
Inmune Bio, Inc.
Phase 1 Terminated
NCT06188208 2026-03-30
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Terminated
NCT03960021 2026-03-27
ARFIM
Institut Bergonié
Phase NA Terminated